ITMN/VRUS/Roche: No change re ITMN’s waffling vis-à-vis the INFORM-3 trial in which Roche would test ritonavir-boosted ITMN-191 + VRUS’ RG7128. As before (see #msg-46797334), Dan Welch plainly emphasized the word may on today’s CC when he said INFORM-3 may begin in 2H10.
I continue to question whether Roche will conduct this trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”